However , it can significantly decrease postintervention and reduction data of FPG , FI , HbA1c , and HOMA-IR .
Heterogeneity was eliminated by subgroup analysis according to baseline BMI .
There was no significant difference in the amelioration of QUICKI between the ITC and control groups .
However , the difference was statistically significant and the heterogeneity was eliminated after subgroup analysis according to intakes of ITC .
Conclusion Supplementation of ITC can ameliorate IR in T2DM , especially in obese T2DM patients , but the effects are controversial in obese patients
Background Insulin resistance ( IR ) is a physiological condition related to type 2 diabetes mellitus ( T2DM ) and obesity , which is associated with high blood insulin and glucose .
Inulin-type carbohydrate ( ITC ) is a kind of fermentable fructan that can reduce glucose and ameliorate IR in an animal model , but the effect in clinical trials is controversial .
Objective The authors conducted a systematic literature review to evaluate the effect of ITC supplementation in ameliorating IR in T2DM and obese patients .
Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial.
OBJECTIVE The objective of this study was to examine the effects of a gastrointestinal microbiome modulator ( GIMM ) containing inulin , β-glucan , blueberry anthocyanins , and blueberry polyphenols on metabolic parameters , fecal markers of gut microbiota , and satiety . DESIGN AND METHODS Thirty overweight or obese individuals aged 18 to 70years , were enrolled in a r and omized controlled trial . Participants consumed the test product or placebo daily for four weeks . Stool sample s were collected and blood was drawn at baseline and week four for assessment s of gut microbiota , satiety hormones , glucose control , and lipid measures . Subjective satiety was assessed weekly . Linear models were used to compare differences from baseline to week four . RESULTS GIMM consumption improved blood glucose tolerance ( p=0.008 ) , and increased satiety ( p=0.03 ) . There were no statistically significant differences in insulin sensitivity , fecal markers of gut microbiota , plasma satiety hormones , or serum lipid concentrations between the groups . However , plasma satiety hormones and fecal short chain fatty acid concentrations increased in the test group compared to the placebo . CONCLUSIONS GIMM consumption for four weeks , increases satiety , and improves glucose tolerance possibly through insulin-independent pathways
However , it can significantly decrease postintervention and reduction data of FPG , FI , HbA1c , and HOMA-IR .
Heterogeneity was eliminated by subgroup analysis according to baseline BMI .
There was no significant difference in the amelioration of QUICKI between the ITC and control groups .
However , the difference was statistically significant and the heterogeneity was eliminated after subgroup analysis according to intakes of ITC .
Conclusion Supplementation of ITC can ameliorate IR in T2DM , especially in obese T2DM patients , but the effects are controversial in obese patients
Background Insulin resistance ( IR ) is a physiological condition related to type 2 diabetes mellitus ( T2DM ) and obesity , which is associated with high blood insulin and glucose .
Inulin-type carbohydrate ( ITC ) is a kind of fermentable fructan that can reduce glucose and ameliorate IR in an animal model , but the effect in clinical trials is controversial .
Objective The authors conducted a systematic literature review to evaluate the effect of ITC supplementation in ameliorating IR in T2DM and obese patients .